GLP-1受体激动剂对CKD患者肾脏与心血管结局的影响:随机试验的系统综述与Meta分析
该系统综述与Meta分析纳入12项RCT、共17,996例基线eGFR<60mL/min/1.73m²的成人患者,评估GLP-1受体激动剂对肾脏复合结局、全因死亡和心血管复合结局的影响。结果显示GLP-1受体激动剂显著降低肾脏复合结局(OR 0.85)、全因死亡(OR 0.77)和心血管复合结局(OR 0.86)风险。
要点
- GLP-1受体激动剂降低CKD患者肾脏复合结局风险(OR 0.85,95%CI 0.77-0.94)。
- GLP-1受体激动剂降低全因死亡风险(OR 0.77,95%CI 0.60-0.98)。
- GLP-1受体激动剂降低心血管复合结局风险(OR 0.86,95%CI 0.74-0.99)。
核心结论
- GLP-1受体激动剂改善CKD患者的肾脏和心血管结局并提高生存率。
研究设计与样本
- 随机对照试验的系统综述与Meta分析,检索至2024年5月25日。
- 从212项筛选研究中纳入12项试验,共17,996例基线eGFR<60mL/min/1.73m²的成人参与者。
- 采用随机效应模型合并OR,使用GRADE系统评估证据确定性。
主要发现
- GLP-1受体激动剂显著降低肾脏复合结局风险(OR 0.85,95%CI 0.77-0.94;P=0.001),异质性低(I²<0.01%)。
- GLP-1受体激动剂降低eGFR下降>30%(OR 0.78;P=0.004)、>40%(OR 0.76;P=0.01)和>50%(OR 0.72;P<0.001)的风险。
- 全因死亡风险降低(OR 0.77,95%CI 0.60-0.98;P=0.03),但异质性高(I²=71.6%)。
- 心血管复合结局风险降低(OR 0.86,95%CI 0.74-0.99;P=0.03;I²=40.3%)。
- 仅限人GLP-1骨架药物的敏感性分析显示获益增强。
关键数值与推荐
- 纳入标准:成人(≥18岁)RCT,基线eGFR<60mL/min/1.73m²,比较GLP-1受体激动剂与对照治疗对肾脏复合结局、全因死亡或心血管复合结局的影响。
临床怎么用
- 对于基线eGFR<60mL/min/1.73m²的CKD患者,GLP-1受体激动剂可考虑用于降低肾脏复合结局、全因死亡和心血管复合结局风险。
局限性
- 肾脏结局定义不一致。
- 多数研究聚焦于糖尿病人群。
- 可能存在发表偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Glucagon-like peptide 1 (GLP-1) receptor agonists improve cardiac and kidney outcomes in patients with diabetes; however, their efficacy in individuals with reduced estimated glomerular filtration rate (eGFR) is uncertain. This study evaluated the effects of GLP-1 receptor agonists on kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD). STUDY DESIGN: Systematic review and meta-analysis of randomized controlled trials (RCTs) reported through May 25, 2024. SETTING & STUDY POPULATIONS: Adult participants in RCTs with baseline eGFR<60mL/min/1.73m2. SELECTION CRITERIA FOR STUDIES: RCTs including adults (≥18 years old) with varying degrees of kidney function, including individuals with CKD characterized by a baseline eGFR of<60mL/min/1.73m2, that compared GLP-1 receptor agonists with control treatments with respect to a composite kidney outcome, all-cause mortality, or a composite CV disease outcome. From among 212 screened studies, 12 trials involving that included participants with baseline eGFR<60mL/min/1.73m2 were included. DATA EXTRACTION: Two independent investigators extracted the data. ANALYTICAL APPROACH: Pooled odds ratios (ORs) for composite kidney outcome, all-cause mortality, and composite CV outcome were estimated using random-effects models. Evidence certainty was assessed using the GRADE system. RESULTS: The analyses included 17,996 RCT participants with baseline eGFR<60mL/min/1.73m2. GLP-1 receptor agonists were significantly associated with a reduced risk of the composite kidney outcome (OR, 0.85 [95% CI, 0.77-0.94]; P=0.001) with low heterogeneity (I2<0.01%). GLP-1 receptor agonists were also associated with a reduced the risk of a>30% eGFR decline (OR, 0.78; P=0.004), a>40% decline (OR, 0.76; P=0.01), and a>50% decline (OR, 0.72; P<0.001). Risk of all-cause mortality was also lower in the GLP-1 receptor agonist group (OR, 0.77 [95% CI, 0.60-0.98], P=0.03), though there was high heterogeneity (I2=71.6%). Composite CV outcomes were also lower with the use of a GLP-1 receptor agonist (OR, 0.86 [95% CI, 0.74-0.99], P=0.03; I2=40.3%). Sensitivity analyses restricted to human GLP-1 backbone agents showed enhanced benefits. LIMITATIONS: Inconsistent kidney outcome definitions, focus on diabetic populations in most studies, and potential publication bias. CONCLUSIONS: GLP-1 receptor agonists improved kidney and CV outcomes, and survival in patients with CKD enrolled in an array of clinical trials. REGISTRATION: Registered at PROSPERO with identification number CRD42023449059. PLAIN-LANGUAGE SUMMARY: Glucagon-like peptide 1 (GLP-1) receptor agonists reduce body weight and improve glycemic control. They also have been shown to protect the heart and kidney in people with diabetes. However, the extrapolation of these findings to those with chronic kidney disease (CKD) is uncertain. This study meta-analyzed data from clinical trials focusing on patients with CKD and noted that GLP-1 receptor agonists may slow kidney disease progression and lower the risk of heart disease, stroke, and death. These findings suggest that GLP-1 receptor agonists offer multiple kidney and cardiovascular benefits to people with CKD.
引用
- Chen JY, Hsu TW, Liu JH, et al. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials. Am J Kidney Dis. 2025. PMID: 39863261. doi:10.1053/j.ajkd.2024.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。